BHVNBiohaven Ltd.vs its industry peers
A metric-by-metric comparison of Biohaven Ltd. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BHVNEsta | $1.9B#7 | — | 153.6x#15 | — | — | 12.7%#8 | — | -6045.0%#16 | — | — | -15.6%#11 | — |
| SRPT | $2.2B#1 | — | 1.4x#2 | 1.2x#2 | 4.3%#10 | -403.3%#12 | -37.5%#6 | -46.7%#11 | -73.0%#5 | — | 20.7%#9 | — |
| NUVB | $2.1B#3 | — | 8.3x#11 | 33.4x#8 | 699.0%#2 | 64.0%#4 | -338.7%#10 | -80.6%#13 | -87.4%#6 | — | 82.5%#5 | — |
| GENB | $2.2B#2 | — | 4.8x#8 | — | — | — | — | 0.0%#2 | — | — | — | — |
| RAPP | $2.0B#4 | — | 4.8x#9 | — | — | -42.4%#10 | — | -26.4%#9 | — | — | 61.6%#7 | — |
| AGIO | $2.0B#5 | — | 2.0x#4 | 37.4x#9 | 48.0%#6 | -161.3%#11 | -873.9%#11 | -40.3%#10 | — | — | -7.0%#10 | — |
| PRGO | $1.9B#8 | — | 0.7x#1 | 0.4x#1 | -2.8%#11 | -729.7%#13 | -26.4%#5 | -56.7%#12 | -20.9%#3 | 4#1 | -30.9%#13 | 8.5%#1 |
| ZYME | $1.9B#6 | — | 24.2x#12 | 18.4x#6 | 38.9%#8 | 33.9%#6 | -87.3%#7 | -100.9%#14 | — | — | 72.3%#6 | — |
| STOK | $1.9B#9 | — | 5.4x#10 | 10.0x#4 | 404.5%#3 | 92.3%#2 | -11.2%#4 | -2.0%#5 | — | — | 26.1%#8 | — |
| SEPN | $1.8B#11 | — | 4.6x#7 | 39.0x#10 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#7 | — | — | 166.3%#3 | — |
| XNCR | $1.8B#10 | — | 3.6x#6 | 14.4x#5 | 13.7%#9 | 60.5%#5 | -141.4%#8 | -18.3%#8 | -31.5%#4 | — | 162.1%#4 | — |
| ANIP | — | 16.2x#1 | — | — | 43.8%#7 | 510.5%#1 | 12.6%#2 | 13.1%#1 | 16.9%#1 | — | -22.1%#12 | — |
| KLRA | $1.7B#12 | — | 1.5x#3 | — | — | — | — | 0.0%#2 | — | — | — | — |
| KARD | $1.7B#13 | — | 2.7x#5 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ETON | $1.6B#14 | — | 35.3x#13 | 20.6x#7 | 104.9%#5 | -20.4%#9 | -1.1%#3 | -9.9%#6 | -1.8%#2 | 4#1 | 226.8%#1 | — |
| ANAB | $1.6B#15 | — | 124.0x#14 | 6.7x#3 | 157.0%#4 | 90.9%#3 | 20.4%#1 | -103.8%#15 | — | — | 180.0%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice